[A different focus on the current status of thrombolysis in pulmonary thromboembolism].
Jerjes Sánchez
C
C
Hospital de Enfermedades Cardiovasculares y del Tórax, Centro Médico Nacional del Norte, IMSS, Monterrey, NL.
Ramírez Rivera
A
A
Gutiérrez Fajardo
P
P
García Castillo
A
A
Cantú Díaz
F
F
Treviño Ortiz
H
H
Villarreal Garza
I
I
D005343:Fibrinolytic Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D006352:Heart Ventricles / Q000503:physiopathology; D006493:Heparin / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000209:etiology; D011655:Pulmonary Embolism / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D013300:Streptokinase / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D015912:Thrombolytic Therapy
D005343:Fibrinolytic Agents; D006493:Heparin; D013300:Streptokinase